,which has shown great success in treating Covid-19. HCQ is being sidelined despite having been approved for malaria in 1955, it is reported to be 91% effective in treating COVID-19, and it is inexpensive, costing only $1 per treatment to manufacture.
All but four states have imposed restrictions on outpatient use of this drug. Major pharmaceutical companies (Novartis, Bayer, Teva, and others) donated nearly 50-million doses of HCQ to the Strategic National Stockpile, but most of it still sits in warehouses because state governments are preventing its use.
Dr. Fauci has been promoting remdesivir, which has only shown modest results with COVID-19 patients, despite taxpayer funding $70-million to Gilead pharmaceutical, the CDC, and the National Institutes of Health to develop it as a treatment for Ebola, which flopped due to severe side effects and almost zero curative effect. Patients must be hospitalized in order to receive remdesivir. Bloomberg reported that the cost to manufacture remdesivir is $9 per treatment, but Gilead said it will cost over $3,000 for a six-vial treatment. Gilead spent over $5-million in lobbying Congress in 2019. -GEG